HeartBeam Launches Public Offering to Fuel Cardiac Tech Innovation

HeartBeam (NASDAQ: BEAT), a pioneering medical technology company focused on cardiac care innovation, has announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The final size and terms of this offering are subject to market conditions, with all securities to be offered by the company itself. The capital raised is intended to advance the commercialization of its groundbreaking FDA-cleared 12-lead synthesized ECG system, a core product that represents a significant leap in portable cardiac monitoring. Additionally, the net proceeds will fuel further development of its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support general working capital and corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for this financial move, which is detailed in the full press release available on the InvestorBrandNetwork website.

The company is at the forefront of transforming cardiac health management with its proprietary technology. HeartBeam is creating the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from three non-coplanar directions and synthesizing these signals into a comprehensive 12-lead ECG. This platform technology is designed for portable devices that can be used anywhere a patient is located, delivering actionable heart intelligence directly to physicians. The innovation allows healthcare providers to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially directing patients to appropriate care more swiftly. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for its 12-lead ECG synthesis software in December 2025. With over 20 issued patents supporting its technology enablement, HeartBeam is positioned to redefine remote cardiac monitoring. For the latest news and updates relating to BEAT, investors and interested parties can visit the company's dedicated newsroom.

This strategic financial initiative underscores HeartBeam's commitment to scaling its innovative solutions in a competitive medtech landscape. The public offering represents a critical step in funding the next phase of growth, from enhancing AI-driven diagnostics to expanding the commercial reach of its FDA-cleared systems. As forward-looking statements in the release caution, the offering involves typical market risks and uncertainties, but the intended use of proceeds highlights a clear roadmap toward improving cardiac care accessibility. The original release on www.newmediawire.com provides complete context, while the InvestorBrandNetwork website hosts essential disclaimers applicable to all published content. By leveraging this capital infusion, HeartBeam aims to accelerate its mission of bringing hospital-grade cardiac monitoring into everyday settings, potentially impacting millions of patients at risk for heart-related events.